Targeting glucocorticoid receptors prevents the effects of early life stress on amyloid pathology and cognitive performance in APP/PS1 mice
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Exposure to chronic stress or elevated glucocorticoid hormone levels in adult life has been associated with cognitive deficits and an increased risk for Alzheimer’s disease (AD). Since exposure to stress during early life enhances stress-responsiveness and lastingly affects cognition in adult life, we here investigated; (i) whether chronic early life stress (ELS) affects AD pathology and cognition in middle-aged APPswe/PS1dE9 mice, and (ii) whether it is still possible to rescue these late effects by briefly blocking glucocorticoid receptors (GRs) at a translationally relevant, middle age. Transgenic APPswe/PS1dE9 mice were subjected to ELS by housing dams and pups with limited nesting and bedding material from postnatal days 2–9 only. In 6- and 12-month-old offspring, this resulted in enhanced hippocampal amyloid-β (Aβ)-40 and -42 levels, and in reduced cognitive flexibility, that correlated well with the Aβ42 levels. In parallel, CORT levels and BACE1 levels were significantly elevated. Surprisingly, blocking GRs for only 3 days at 12 months of age reduced CORT levels, reduced hippocampal Aβ40 and -42, and β-site APP-cleaving enzyme 1 (BACE1) levels, and notably rescued the cognitive deficits in 12-month-old APPswe/PS1dE9 mice. These mouse data demonstrate that exposure to stress during the sensitive period early in life influences later amyloid pathology and cognition in genetically predisposed, mutant mice, and as such, may increase AD vulnerability. The fact that a short treatment with a GR antagonist at middle age lastingly reduced Aβ levels and rescued the cognitive deficits after ELS, highlights the therapeutic potential of this drug for reducing amyloid pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In rat research, the administration of a glucocorticoid receptor antagonist resulted in improved cognition and reduced AD pathologies [83].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [83]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This evidence indicates that glucocorticoid signaling influences the likelihood and the extent of AD pathologies.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Baumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.016 · Cited by 1,660
Matthews, F. E., Arthur, A., Barnes, L. E., Bond, J., Jagger, C., Robinson, L., & Brayne, C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61570-6 · Cited by 1,155
The stress system in the human brain in depression and neurodegeneration
Swaab, D. F., Bao, A.-M., & Lucassen, P. J. (2005) · Ageing Research Reviews · doi:10.1016/j.arr.2005.03.003 · Cited by 984 · cited 1×
“Notwithstanding, HPA dysfunction does not seem to worsen further with disease progression in patients 43,44 , implying that early alterations in HPA axis, likely acting via glucocorticoids, contribute to the onset and subsequent acceleration of AD pathogenesis.”
BackgroundSelf-citationCo-expression of multiple transgenes in mouse CNS: a comparison of strategies
Jankowsky, J. L., Slunt, H. H., Ratovitski, T., Jenkins, N. A., Copeland, N. G., & Borchelt, D. R. (2001) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00067-3 · Cited by 746 · cited 1×
“…decline 19,20 , we tested the hypothesis that ELS — induced by housing mice with limited nesting and bedding material from postnatal days (PND) 2 – 9 21 – 24 — increases the development of AD pathology and cognitive decline in APPswe/ PS1dE9 mice, a classic mouse model for amyloid pathology 25 .”
BackgroundGlucocorticoids increase amyloid-β and tau pathology in a mouse model of alzheimer’s disease
Green, K. N., Billings, L. M., Roozendaal, B., McGaugh, J. L., & LaFerla, F. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2797-06.2006 · Cited by 623 · cited 1×
“At 12 months of age, when the amyloid plaque pathology had progressed substantially, SDS-soluble Aβ42, but not Aβ40, levels were significantly elevated in ELS-APPswe/PS1dE9 mice (Aβ40: t(16)= SDS-soluble fraction”
BackgroundMeta-analysis of modifiable risk factors for Alzheimer's disease
Xu, W., Tan, L., Wang, H.-F., Jiang, T., Tan, M.-S., Tan, L., Zhao, Q.-F., Li, J.-Q., Wang, J., & Yu, J.-T. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-310548 · Cited by 573
A Novel Mouse Model for Acute and Long-Lasting Consequences of Early Life Stress
Rice, C. J., Sandman, C. A., Lenjavi, M. R., & Baram, T. Z. (2008) · Endocrinology · doi:10.1210/en.2008-0633 · Cited by 521 · cited 1×
“…decline 19,20 , we tested the hypothesis that ELS — induced by housing mice with limited nesting and bedding material from postnatal days (PND) 2 – 9 21 – 24 — increases the development of AD pathology and cognitive decline in APPswe/ PS1dE9 mice, a classic mouse model for amyloid pathology 25 .”
BackgroundToward understanding how early-life stress reprograms cognitive and emotional brain networks
Chen, Y., & Baram, T. Z. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.181 · Cited by 474 · cited 2×
“001), while Aβ40 levels were comparable between vehicle and mifepristone-treated APPswe/PS1dE9 mice (treatment effect: F(1,20)= 0.”
BackgroundResultPlasma Cortisol and Progression of Dementia in Subjects With Alzheimer-Type Dementia
Csernansky, J. G., Dong, H., Fagan, A. M., Wang, L., Xiong, C., Holtzman, D. M., & Morris, J. C. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2164 · Cited by 426 · cited 1×
“57) or cornu ammonis (CA) subregions (t(9)= 0.”
BackgroundPlasma Cortisol and Progression of Dementia in Subjects With Alzheimer-Type Dementia
Csernansky, J. G., Dong, H., Fagan, A. M., Wang, L., Xiong, C., Holtzman, D. M., & Morris, J. C. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.12.2164 · Cited by 426
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.9.1372 · Cited by 411 · cited 1×
“04) relative to Ctrl-APPswe/ PS1dE9 mice, but was not different in the dentate gyrus (DG) (t(11)= 0.”
Self-citationThe Consequences of Early‐Life Adversity: Neurobiological, Behavioural and Epigenetic Adaptations
Maccari, S., Krugers, H. J., Morley‐Fletcher, S., Szyf, M., & Brunton, P. J. (2014) · Journal of Neuroendocrinology · doi:10.1111/jne.12175 · Cited by 351
Self-citationImpaired spatial learning in the APPSwe + PSEN1ΔE9 bigenic mouse model of Alzheimer’s disease
Reiserer, R. S., Harrison, F. E., Syverud, D. C., & McDonald, M. P. (2007) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2006.00221.x · Cited by 324
Executive function deficits in mild Alzheimer's disease.
Lafleche, G., & Albert, M. S. (1995) · Neuropsychology · doi:10.1037//0894-4105.9.3.313 · Cited by 286
Naninck, E. F. G., Hoeijmakers, L., Kakava-Georgiadou, N., Meesters, A., Lazic, S. E., Lucassen, P. J., & Korosi, A. (2015) · Hippocampus · doi:10.1002/hipo.22374 · Cited by 285 · cited 1×
“…decline 19,20 , we tested the hypothesis that ELS — induced by housing mice with limited nesting and bedding material from postnatal days (PND) 2 – 9 21 – 24 — increases the development of AD pathology and cognitive decline in APPswe/ PS1dE9 mice, a classic mouse model for amyloid pathology 25 .”
BackgroundSelf-citationSotiropoulos, I., Catania, C., Pinto, L. G., Silva, R., Pollerberg, G. E., Takashima, A., Sousa, N., & Almeida, O. F. X. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0730-11.2011 · Cited by 257
Cortisol and Alzheimer's disease, I: Basal studies
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.3.300 · Cited by 246 · cited 1×
“In addition, elevated basal levels of circulating cortisol in the early disease stages 37 – 39 , as well as the failure to suppress cortisol after the dexamethasone challenge 40 – 42 , indicates that HPA axis activity is altered in AD patients.”
BackgroundClinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
Flores, B. H., Kenna, H., Keller, J., Solvason, H. B., & Schatzberg, A. F. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300884 · Cited by 203 · cited 1×
“It has further been tested in preliminary studies on (aspects of) AD 26 and psychotic depression 27,28 (see ref.”
Hypothalamic‐Pituitary‐Adrenal (HPA) Axis and Aging
Gupta, D., & Morley, J. E. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130049 · Cited by 184 · cited 1×
“Age-related cognitive decline has previously been associated with age-related increases in HPA axis activity 35,36 .”
BackgroundGene structure and organization of the human β‐secretase ( BACE ) promoter
Sambamurti, K., Kinsey, R., Maloney, B., Ge, Y.-W., & Lahiri, D. K. (2004) · The FASEB Journal · doi:10.1096/fj.03-1378fje · Cited by 179 · cited 1×
“The rate-limiting enzyme involved in processing of APP to A β is BACE1, an enzyme that also contains glucocorticoid-binding sites 49 .”
BackgroundThe amyloidogenic potential and behavioral correlates of stress
Catania, C., Sotiropoulos, I., Silva, R., Onofri, C., Breen, K. C., Sousa, N., & Almeida, O. F. X. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002101 · Cited by 176 · cited 1×
“In 6 and 12 month-old-mice of age, ELS significantly increased BACE1 expression in APPswe/PS1dE9 mice relative to Ctrl-APPswe/PS1dE9 mice (6 months: t(13)= 2.”
BackgroundCognitive Dysfunction, Hippocampal Atrophy and Glucocorticoid Feedback in Alzheimer’s Disease
Elgh, E., Lindqvist Åstot, A., Fagerlund, M., Eriksson, S., Olsson, T., & Näsman, B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.017 · Cited by 159 · cited 2×
“No differences in the time required to locate the exit hole were present between the groups (reversal learning: condition effect: F(1,39)= 1.”
BackgroundHerbert, J., & Lucassen, P. J. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2015.12.001 · Cited by 150 · cited 2×
“They are often increased in AD, notably already in early stages of the disease 9,10 , and dysregulation of the hypothalamus – pituitary – adrenal (HPA) axis is also associated with a higher AD risk 8,10,11 .”
BackgroundSelf-citationTau protein is essential for stress-induced brain pathology
Lopes, S., Vaz-Silva, J., Pinto, V., Dalla, C., Kokras, N., Bedenk, B., Mack, N., Czisch, M., Almeida, O. F. X., Sousa, N., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600953113 · Cited by 147 · cited 1×
“However, the levels of Aβ42 remained significantly reduced in ELS mice that had been treated with mifepristone (F(1,18)= 15.”
Background(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.4.442 · Cited by 141
Swanwick, G. R. J., Kirby, M., Bruce, I., Buggy, F., Coen, R. F., Coakley, D., & Lawlor, B. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.2.286 · Cited by 131
Deregulation of hypothalamic-pituitary-adrenal axis functions in an Alzheimer's disease rat model
Brureau, A., Zussy, C., Delair, B., Ogier, C., IXART, G., Maurice, T., & Givalois, L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.015 · Cited by 120 · cited 1×
“Age-related cognitive decline has previously been associated with age-related increases in HPA axis activity 35,36 .”
BackgroundThe use of mifepristone in the treatment of neuropsychiatric disorders
DeBattista, C., & Belanoff, J. K. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.02.006 · Cited by 103 · cited 1×
“29 for a review about the function and applicability of mifepristone in humans).”
BackgroundArp, J. M., ter Horst, J. P., Loi, M., den Blaauwen, J. L., Bangert, E., Fernández, G., Joëls, M., Oitzl, M. S., & Krugers, H. J. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.05.009 · Cited by 102
Self-citationBaglietto-Vargas, D., Medeiros, R., Martinez-Coria, H., LaFerla, F. M., & Green, K. N. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.12.003 · Cited by 99 · cited 2×
“Rodent studies further demonstrate that exposure to stress and/or elevated GC levels at an adult age impairs cognition and enhances A β levels both in mutant 12 – 16 and in wild type (WT) animals 17,18 .”
BackgroundResultSotiropoulos, I., Catania, C., Riedemann, T., Fry, J. P., Breen, K. C., Michaelidis, T. M., & Almeida, O. F. X. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05613.x · Cited by 97
Kulstad, J. J., McMillan, P. J., Leverenz, J. B., Cook, D. G., Green, P. S., Peskind, E. R., Wilkinson, C. W., Farris, W., Mehta, P. D., & Craft, S. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.139 · Cited by 97
Sierksma, A. S. R., Prickaerts, J., Chouliaras, L., Rostamian, S., Delbroek, L., Rutten, B. P. F., Steinbusch, H. W. M., & van den Hove, D. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.05.012 · Cited by 92 · cited 1×
“Importantly, no differences were observed between the groups in walking distance or speed during habituation (genotype effect: F (1,46)= 2.”
BackgroundMarlatt, M. W., Potter, M. C., Bayer, T. A., van Praag, H., & Lucassen, P. J. (2013) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_237 · Cited by 92 · cited 1×
“Mifepristone reduced both basal plasma CORT levels (treatment effect: F(1,31)= 111.”
BackgroundSelf-citationCentral and Peripheral Endorphins: Basic and Clinical Aspects
Davis, G. C. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.5.664-a · Cited by 91
Lanté, F., Chafaï, M., Raymond, E., Pereira, A. R. S., Mouska, X., Kootar, S., Barik, J., Bethus, I., & Marie, H. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.25 · Cited by 87
Hüttenrauch, M., Baches, S., Gerth, J., Bayer, T. A., Weggen, S., & Wirths, O. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-142463 · Cited by 86 · cited 1×
“During acquisition learning, APPswe/PS1dE9 mice were slower in acquisition learning on the Barnes maze (F(1,32)= 14.”
BackgroundSelf-citation3xTg-AD Mice Exhibit an Activated Central Stress Axis During Early-Stage Pathology
Hebda-Bauer, E. K., Simmons, T. A., Sugg, A., Ural, E., Stewart, J. A., Beals, J. L., Wei, Q., Watson, S. J., & Akil, H. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121438 · Cited by 78 · cited 2×
“This was confirmed by the probe trial, where ELSAPPswe/PS1dE9 mice spend less time in the exit quadrant than ELS-WT mice (genotype effect: F(1,45)= 4.”
BackgroundResultNongenetic Factors as Modifiers of the Age of Onset of Familial Alzheimer’s Disease
Mejia, S., Giraldo, M., Pineda, D., Lopera, F., & Ardila, A. (2003) · International Psychogeriatrics · doi:10.1017/s1041610203009591 · Cited by 73 · cited 1×
“5d), while BACE1 levels in the hippocampus were also reduced (t(6)= 3.”
BackgroundEfficacy and Safety of Mifepristone for the Treatment of Psychotic Depression
Blasey, C. M., Block, T. S., Belanoff, J. K., & Roe, R. L. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182239191 · Cited by 73
Increased cerebrospinal fluid cortisol level in Alzheimer's disease is not related to depression
Hoogendijk, W. J. G., Meynen, G., Endert, E., Hofman, M. A., & Swaab, D. F. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.07.017 · Cited by 73 · cited 1×
“All mice could identify the exit quadrant in the probe trial, as assessed by significantly more than 25% (chance level) of time spend in the exit quadrant (Ctrl-WT: t(10)= 10.”
BackgroundNäsman, B., Olsson, T., Fagerlund, M., Eriksson, S., Viitanen, M. H., & Carlström, K. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00173-5 · Cited by 72 · cited 3×
“Determining the total area under the curve of the plasma CORT response from 0 to 90min after stressor onset revealed that ELS-APPswe/ PS1dE9 mice were exposed to elevated plasma CORT levels after stress, relative to Ctrl-APPswe/PS1dE9 mice, and relative to ELS-WT mice (interaction effect: F(1,40) = 22.”
BackgroundMethodInfluentialNäsman, B., Olsson, T., Viitanen, M. H., & Carlström, K. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(94)00054-e · Cited by 62 · cited 2×
“88), (average: condition effect: F(1,41)= 1.”
BackgroundArsenault‐Lapierre, G., Chertkow, H. M., & LUPIEN, S. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.07.011 · Cited by 61 · cited 1×
“Stereological quantification revealed that the percentage of area covered by Aβ plaques was significantly increased in the subiculum of 6-month-old ELS-APPswe/PS1dE9 mice (t(7)= 2.”
BackgroundLesuis, S. L., Maurin, H., Borghgraef, P., Lucassen, P. J., Leuven, F. V., & Krugers, H. J. (2016) · Oncotarget · doi:10.18632/oncotarget.9776 · Cited by 58
Self-citationMifepristone (RU 486) for Alzheimer’s disease
Pomara, N., Doraiswamy, P. M., Tun, H., & Ferris, S. (2002) · Neurology · doi:10.1212/wnl.58.9.1436 · Cited by 53 · cited 2×
“So far, a small clinical trial in AD patients and old macaques monkeys reported improvements in cognition after mifepristone treatment 26,50 , although the short time window and small sample size warrant caution in interpreting these results.”
BackgroundResultMartišová, E., Aisa, B., Gereñu, G., & Ramírez, M. J. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310040007 · Cited by 52 · cited 3×
“001), and displayed significantly longer latencies to find the exit hole over training days 2–4 (day 2: F(1,47)= 31.”
BackgroundMethodResultInfluentialHigh plasma levels of cortisol in patients with senile dementia of the Alzheimer's type.
Masugi, F., Ogihara, T., Sakaguchi, K., Otsuka, A., Tsuchiya, Y., Morimoto, S., Kumahara, Y., Saeki, S., & Nishide, M. (1989) · PubMed · Cited by 48
Lesuis, S. L., van Hoek, B. A. C. E., Lucassen, P. J., & Krugers, H. J. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.05.016 · Cited by 30
Self-citationScreening for Depression in Elderly Patients
Swanwick, G., & Wrigley, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.994 · Cited by 28
Grigoryan, G., Biella, G., Albani, D., Forloni, G., & Segal, M. (2014) · Neurodegenerative Diseases · doi:10.1159/000354231 · Cited by 15
Cited by
The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders
Knezevic, E., Nenic, K., Milanovic, V., & Knezevic, N. N. (2023) · Cells · doi:10.3390/cells12232726 · Cited by 564
“In rat research, the administration of a glucocorticoid receptor antagonist resulted in improved cognition and reduced AD pathologies [83].”
BackgroundHigh Cortisol and the Risk of Dementia and Alzheimer’s Disease: A Review of the Literature
Ouanes, S., & Popp, J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00043 · Cited by 470
“In a similar way, mifepristone has been shown to reduce the hippocampal Aβ levels and rescue the cognitive deficits induced by early life stress in APP/PS1 transgenic mice (Lesuis et al., 2018).”
Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810572 · Cited by 202
“APPswe/PS1dE9 mouse models of AD increased the brain levels of Aβ40 and Aβ42 in the hippocampus, and reduced cognitive abilities, an effect alleviated by the glucocorticoid receptors blocker, mifepristone [47].”
BackgroundLesuis, S. L., Hoeijmakers, L., Korosi, A., de Rooij, S. R., Swaab, D. F., Kessels, H. W., Lucassen, P. J., & Krugers, H. J. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0422-7 · Cited by 115
Self-citationMilligan Armstrong, A., Porter, T., Quek, H., White, A., Haynes, J., Jackaman, C., Villemagne, V., Munyard, K., Laws, S. M., Verdile, G., et al. (2021) · Biological Reviews · doi:10.1111/brv.12750 · Cited by 116
Metadata
- Authors
- Lesuis, S. L., Weggen, S., Baches, S., Lucassen, P. J., & Krugers, H. J.
- Affiliations
- University of Amsterdam (NL)
- Heinrich Heine University Düsseldorf (DE)
- Corresponding author
- Lesuis, Sylvie L
- Venue
- Translational Psychiatry
- Published
- 2018-03-01
- Volume
- 8
- Issue
- 1
- Pages
- 53-53
- ISSN
- 2158-3188 (ISSN-L)
- PMC
- PMC5830444
- OpenAlex
- W2802451112
- Semantic Scholar
- b2f7b7063e614a266affeea3342d5180ddc77e1b
- Cited by
- 85
- References
- 52
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 14 · 2023: 11 · 2022: 12 · 2021: 10 · 2020: 8 · 2019: 13 · 2018: 5
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Translational Psychiatry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Internationale Stichting Alzheimer Onderzoek (12534)
- Alzheimer Nederland (12534)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- early life stress, glucocorticoid receptor antagonism, Alzheimer's disease, amyloid-beta, APP/PS1 mice, cognitive flexibility, hippocampus, BACE1, corticosterone, glucocorticoid stress response
- MeSH terms
- Age Factors, Animals, Behavior, Animal, Corticosterone, Disease Models, Animal, Female, Hippocampus, Hormone Antagonists, Male, Mice, Inbred C57BL, Mice, Transgenic, Peptide Fragments, Receptors, Glucocorticoid, Stress, Psychological, Mifepristone, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Mice, Amyloid Precursor Protein Secretases, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.